Polymerase mechanism-based method of viral attenuation

Cheri A. Lee, Avery August, Jamie Jon Arnold, Craig Eugene Cameron

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Vaccines remain the most effective way of preventing infection and spread of infectious diseases. These prophylactics have been used for centuries but still to this day only three main design strategies exist: (1) live attenuated virus (LAV) vaccines, (2) killed or inactivated virus vaccines, (3) and subunit vaccines of the three, the most efficacious vaccines remain LAVs. LAVs replicate in relevant tissues, elicit strong cellular and humoral responses, and often confer lifelong immunity. While this vaccine strategy has produced the majority of successful vaccines in use today, there are also important safety concerns to consider with this approach. In the past, the development of LAVs has been empirical. Blind passage of viruses in various cell types results in the accumulation of multiple attenuating mutations leaving the molecular mechanisms of attenuation unknown. Also, due to the high error rate of RNA viruses and selective pressures of the host environment, these LAVs, derived from such viruses, can potentially revert back to wild-type virulence. This not only puts the vaccinee at risk, but if shed can put those that are unvaccinated at risk as well. While these vaccines have been successful there still remains a need for a rational design strategy by which to create additional LAVs. One approach for rational vaccine design involves increasing the fidelity of the viral RdRp. Increased fidelity decreases the viral mutational frequency thereby reducing the genetic variation the virus needs in order to evade the host imposed bottlenecks to infection. While polymerase mutants exist which decrease viral mutation frequency the mutations are not in conserved regions of the polymerase, which doesn’t lend itself toward using a common mutant approach toward developing a universal vaccine strategy for all RNA viruses. We have identified a conserved lysine residue in the active site of the PV RdRp that acts as a general acid during nucleotide incorporation. Mutation from a lysine to an arginine results in a high fidelity polymerase that replicates slowly thus creating an attenuated virus that is genetically stable and less likely to revert to a wild-type phenotype. This chapter provides detailed methods in which to identify the conserved lysine residue and evaluating fidelity and attenuation in cell culture (in vitro) and in the PV transgenic murine model (in vivo).

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages83-104
Number of pages22
DOIs
StatePublished - Jan 1 2016

Publication series

NameMethods in Molecular Biology
Volume1349
ISSN (Print)1064-3745

Fingerprint

Vaccines
Viruses
Lysine
RNA Viruses
Mutation
Attenuated Vaccines
Inactivated Vaccines
Subunit Vaccines
Mutation Rate
Infection
Communicable Diseases
Virulence
Arginine
Immunity
Catalytic Domain
Nucleotides
Cell Culture Techniques
Phenotype
Safety
Acids

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics

Cite this

Lee, C. A., August, A., Arnold, J. J., & Cameron, C. E. (2016). Polymerase mechanism-based method of viral attenuation. In Methods in Molecular Biology (pp. 83-104). (Methods in Molecular Biology; Vol. 1349). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-3008-1_6
Lee, Cheri A. ; August, Avery ; Arnold, Jamie Jon ; Cameron, Craig Eugene. / Polymerase mechanism-based method of viral attenuation. Methods in Molecular Biology. Humana Press Inc., 2016. pp. 83-104 (Methods in Molecular Biology).
@inbook{b40ae26a75444828a1e80f9787925b44,
title = "Polymerase mechanism-based method of viral attenuation",
abstract = "Vaccines remain the most effective way of preventing infection and spread of infectious diseases. These prophylactics have been used for centuries but still to this day only three main design strategies exist: (1) live attenuated virus (LAV) vaccines, (2) killed or inactivated virus vaccines, (3) and subunit vaccines of the three, the most efficacious vaccines remain LAVs. LAVs replicate in relevant tissues, elicit strong cellular and humoral responses, and often confer lifelong immunity. While this vaccine strategy has produced the majority of successful vaccines in use today, there are also important safety concerns to consider with this approach. In the past, the development of LAVs has been empirical. Blind passage of viruses in various cell types results in the accumulation of multiple attenuating mutations leaving the molecular mechanisms of attenuation unknown. Also, due to the high error rate of RNA viruses and selective pressures of the host environment, these LAVs, derived from such viruses, can potentially revert back to wild-type virulence. This not only puts the vaccinee at risk, but if shed can put those that are unvaccinated at risk as well. While these vaccines have been successful there still remains a need for a rational design strategy by which to create additional LAVs. One approach for rational vaccine design involves increasing the fidelity of the viral RdRp. Increased fidelity decreases the viral mutational frequency thereby reducing the genetic variation the virus needs in order to evade the host imposed bottlenecks to infection. While polymerase mutants exist which decrease viral mutation frequency the mutations are not in conserved regions of the polymerase, which doesn’t lend itself toward using a common mutant approach toward developing a universal vaccine strategy for all RNA viruses. We have identified a conserved lysine residue in the active site of the PV RdRp that acts as a general acid during nucleotide incorporation. Mutation from a lysine to an arginine results in a high fidelity polymerase that replicates slowly thus creating an attenuated virus that is genetically stable and less likely to revert to a wild-type phenotype. This chapter provides detailed methods in which to identify the conserved lysine residue and evaluating fidelity and attenuation in cell culture (in vitro) and in the PV transgenic murine model (in vivo).",
author = "Lee, {Cheri A.} and Avery August and Arnold, {Jamie Jon} and Cameron, {Craig Eugene}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-3008-1_6",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "83--104",
booktitle = "Methods in Molecular Biology",

}

Lee, CA, August, A, Arnold, JJ & Cameron, CE 2016, Polymerase mechanism-based method of viral attenuation. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1349, Humana Press Inc., pp. 83-104. https://doi.org/10.1007/978-1-4939-3008-1_6

Polymerase mechanism-based method of viral attenuation. / Lee, Cheri A.; August, Avery; Arnold, Jamie Jon; Cameron, Craig Eugene.

Methods in Molecular Biology. Humana Press Inc., 2016. p. 83-104 (Methods in Molecular Biology; Vol. 1349).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Polymerase mechanism-based method of viral attenuation

AU - Lee, Cheri A.

AU - August, Avery

AU - Arnold, Jamie Jon

AU - Cameron, Craig Eugene

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Vaccines remain the most effective way of preventing infection and spread of infectious diseases. These prophylactics have been used for centuries but still to this day only three main design strategies exist: (1) live attenuated virus (LAV) vaccines, (2) killed or inactivated virus vaccines, (3) and subunit vaccines of the three, the most efficacious vaccines remain LAVs. LAVs replicate in relevant tissues, elicit strong cellular and humoral responses, and often confer lifelong immunity. While this vaccine strategy has produced the majority of successful vaccines in use today, there are also important safety concerns to consider with this approach. In the past, the development of LAVs has been empirical. Blind passage of viruses in various cell types results in the accumulation of multiple attenuating mutations leaving the molecular mechanisms of attenuation unknown. Also, due to the high error rate of RNA viruses and selective pressures of the host environment, these LAVs, derived from such viruses, can potentially revert back to wild-type virulence. This not only puts the vaccinee at risk, but if shed can put those that are unvaccinated at risk as well. While these vaccines have been successful there still remains a need for a rational design strategy by which to create additional LAVs. One approach for rational vaccine design involves increasing the fidelity of the viral RdRp. Increased fidelity decreases the viral mutational frequency thereby reducing the genetic variation the virus needs in order to evade the host imposed bottlenecks to infection. While polymerase mutants exist which decrease viral mutation frequency the mutations are not in conserved regions of the polymerase, which doesn’t lend itself toward using a common mutant approach toward developing a universal vaccine strategy for all RNA viruses. We have identified a conserved lysine residue in the active site of the PV RdRp that acts as a general acid during nucleotide incorporation. Mutation from a lysine to an arginine results in a high fidelity polymerase that replicates slowly thus creating an attenuated virus that is genetically stable and less likely to revert to a wild-type phenotype. This chapter provides detailed methods in which to identify the conserved lysine residue and evaluating fidelity and attenuation in cell culture (in vitro) and in the PV transgenic murine model (in vivo).

AB - Vaccines remain the most effective way of preventing infection and spread of infectious diseases. These prophylactics have been used for centuries but still to this day only three main design strategies exist: (1) live attenuated virus (LAV) vaccines, (2) killed or inactivated virus vaccines, (3) and subunit vaccines of the three, the most efficacious vaccines remain LAVs. LAVs replicate in relevant tissues, elicit strong cellular and humoral responses, and often confer lifelong immunity. While this vaccine strategy has produced the majority of successful vaccines in use today, there are also important safety concerns to consider with this approach. In the past, the development of LAVs has been empirical. Blind passage of viruses in various cell types results in the accumulation of multiple attenuating mutations leaving the molecular mechanisms of attenuation unknown. Also, due to the high error rate of RNA viruses and selective pressures of the host environment, these LAVs, derived from such viruses, can potentially revert back to wild-type virulence. This not only puts the vaccinee at risk, but if shed can put those that are unvaccinated at risk as well. While these vaccines have been successful there still remains a need for a rational design strategy by which to create additional LAVs. One approach for rational vaccine design involves increasing the fidelity of the viral RdRp. Increased fidelity decreases the viral mutational frequency thereby reducing the genetic variation the virus needs in order to evade the host imposed bottlenecks to infection. While polymerase mutants exist which decrease viral mutation frequency the mutations are not in conserved regions of the polymerase, which doesn’t lend itself toward using a common mutant approach toward developing a universal vaccine strategy for all RNA viruses. We have identified a conserved lysine residue in the active site of the PV RdRp that acts as a general acid during nucleotide incorporation. Mutation from a lysine to an arginine results in a high fidelity polymerase that replicates slowly thus creating an attenuated virus that is genetically stable and less likely to revert to a wild-type phenotype. This chapter provides detailed methods in which to identify the conserved lysine residue and evaluating fidelity and attenuation in cell culture (in vitro) and in the PV transgenic murine model (in vivo).

UR - http://www.scopus.com/inward/record.url?scp=84944452671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944452671&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3008-1_6

DO - 10.1007/978-1-4939-3008-1_6

M3 - Chapter

C2 - 26458831

AN - SCOPUS:84944452671

T3 - Methods in Molecular Biology

SP - 83

EP - 104

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -

Lee CA, August A, Arnold JJ, Cameron CE. Polymerase mechanism-based method of viral attenuation. In Methods in Molecular Biology. Humana Press Inc. 2016. p. 83-104. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-3008-1_6